Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EU Funding Helps Fight Liver Cancer

22.02.2005


The fight against liver cancer, one of the leading causes of cancer death worldwide, is being helped by 2.5 million euros from the EU’s Framework Programme.



PONT (Parallel Optimisation of New Technologies for Post-Genomics Drug Discovery) is a three-year specific targeted research project involving four biotechnology companies and two academic partners from the UK, Austria and Germany. It aims to bridge the gap in the drug development pipeline using a new approach in post-genomics drug discovery. The project combines optimal technologies with the best scientific expertise to develop new medical therapies.

The overall project will concentrate on three areas where Europe is in a relatively favourable position compared with the US - human tissue resources, ribonucleic acid (RNA) technology, and structural proteomics. However, the initial focus will be on the development of genomics targets in hepatocellular carcinoma (HCC) or liver cancer as it is one of the leading causes of cancer death worldwide and has a very poor prognosis.


“PONT combines cutting-edge technologies and associated know-how developed specifically by the project partners in a collaborative multinational effort to establish a unique metaplatform for post-genomics drug development” says Peter Kane, Senior Director of Research Operations at Tripos Discovery Research - one of the UK project partners. “The project will provide a new paradigm for drug development, resulting in a dramatic reduction in late-stage drug target attrition for preclinical development activities and therefore shortening the time to develop new drugs by two years or more. The programme addresses the general lack of efficiency in converting promising targets from genomics research into effective new drugs, potentially achieving significant time and cost savings that will increase European competitiveness in the biotechnology Industry at many levels.”

“Pont will not only bridge the gap between the wealth of genomics targets and shortcomings in development of these targets, but also the gap between a fragmented biotech industry and the few very big pharma companies. The project integrates four companies in a highly interactive workflow that will provide a model establishing a strong position for biotech precision technology platforms.”

As well as increasing the overall competitiveness of the European biotechnology industry, the successful implementation of the PONT strategy will also provide important and valuable new therapeutic prospects. In contrast to the traditional approach, PONT will undertake pre-clinical drug development with a parallel instead of a sequential approach. This will save years when it comes to the trials.

“The PONT project shows the value of investing EU funding in effective research and development that will bring benefits to us all”, says Claire Horton, FP6UKs National Contact Point for the Life Sciences, Genomics and Biotechnology for Health programme. “It provides the opportunity to bring together the expertise of scientists from throughout Europe, enabling them to work together in finding solutions to many of today’s problems.

“The current Framework Programme (FP6) runs until 2006 and organisations wanting free, easy to access, information on the €19bn (euros) of funding available to support internationally collaborative R&D should log on to http://fp6uk.ost.gov.uk or call central telephone support on 0870 600 6080.”

Dave Sanders | alfa
Further information:
http://fp6uk.ost.gov.uk

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>